This WCLC 2026 interview with Prof. Roy S. Herbst reviews the eight-year ADAURA update and its implications for adjuvant osimertinib in resected EGFR-mutant non-small cell lung cancer.
Organized by the International Association for the Study of Lung Cancer (IASLC), the World Conference on Lung Cancer (WCLC) brings together clinicians, researchers, nurses, and other thoracic oncology professionals to share major advances in lung cancer research and clinical care. WCLC 2026 took place in Seoul, Republic of Korea, from September 12 to 15.
Prof. Roy S. Herbst is Director of Dartmouth Cancer Center and Professor of Medicine and of Microbiology and Immunology at the Geisel School of Medicine at Dartmouth. Prof. Herbst’s research focuses on targeted therapy, immunotherapy, and biomarker-guided precision treatment for lung cancer.
Key highlights from this clip:
● Key findings from the exploratory eight-year ADAURA update
● Long-term outcomes following three years of adjuvant osimertinib
● Subgroup findings across stage IB–IIIA EGFR-mutant NSCLC
● The additional insights gained beyond the five-year overall survival analysis
● The optimal duration of adjuvant EGFR-targeted therapy
● MRD-guided personalization of postoperative treatment
This video is intended for medical education and professional discussion.